000600080 001__ 600080
000600080 005__ 20250724132556.0
000600080 0247_ $$2doi$$a10.1021/acs.jmedchem.2c01887
000600080 0247_ $$2ISSN$$a0095-9065
000600080 0247_ $$2ISSN$$a0022-2623
000600080 0247_ $$2ISSN$$a1520-4804
000600080 0247_ $$2ISSN$$a1943-2992
000600080 0247_ $$2datacite_doi$$a10.3204/PUBDB-2023-07733
000600080 0247_ $$2altmetric$$aaltmetric:143423326
000600080 0247_ $$2pmid$$apmid:36883902
000600080 0247_ $$2WOS$$aWOS:000947818200001
000600080 0247_ $$2openalex$$aopenalex:W4323531069
000600080 037__ $$aPUBDB-2023-07733
000600080 041__ $$aEnglish
000600080 082__ $$a610
000600080 1001_ $$aGrygier, Przemyslaw$$b0
000600080 245__ $$aSilmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective
000600080 260__ $$aWashington, DC$$bACS$$c2023
000600080 3367_ $$2DRIVER$$aarticle
000600080 3367_ $$2DataCite$$aOutput Types/Journal article
000600080 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1704798876_313857
000600080 3367_ $$2BibTeX$$aARTICLE
000600080 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000600080 3367_ $$00$$2EndNote$$aJournal Article
000600080 520__ $$aA clinical casein kinase 2 inhibitor, CX-4945 (silmitasertib), shows significant affinity toward the DYRK1A and GSK3β kinases, involved in down syndrome phenotypes, Alzheimer’s disease, circadian clock regulation, and diabetes. This off-target activity offers an opportunity for studying the effect of the DYRK1A/GSK3β kinase system in disease biology and possible line extension. Motivated by the dual inhibition of these kinases, we solved and analyzed the crystal structures of DYRK1A and GSK3β with CX-4945. We built a quantum-chemistry-based model to rationalize the compound affinity for CK2α, DYRK1A, and GSK3β kinases. Our calculations identified a key element for CK2α’s subnanomolar affinity to CX-4945. The methodology is expandable to other kinase selectivity modeling. We show that the inhibitor limits DYRK1A- and GSK3β-mediated cyclin D1 phosphorylation and reduces kinase-mediated NFAT signaling in the cell. Given the CX-4945’s clinical and pharmacological profile, this inhibitory activity makes it an interesting candidate with potential for application in additional disease areas.
000600080 536__ $$0G:(DE-HGF)POF4-6G3$$a6G3 - PETRA III (DESY) (POF4-6G3)$$cPOF4-6G3$$fPOF IV$$x0
000600080 588__ $$aDataset connected to CrossRef, Journals: bib-pubdb1.desy.de
000600080 693__ $$0EXP:(DE-H253)P-P11-20150101$$1EXP:(DE-H253)PETRAIII-20150101$$6EXP:(DE-H253)P-P11-20150101$$aPETRA III$$fPETRA Beamline P11$$x0
000600080 7001_ $$00000-0001-8430-8608$$aPustelny, Katarzyna$$b1
000600080 7001_ $$aNowak, Jakub$$b2
000600080 7001_ $$aGolik, Przemyslaw$$b3
000600080 7001_ $$0P:(DE-H253)PIP1086294$$aPopowicz, Grzegorz M.$$b4
000600080 7001_ $$aPlettenburg, Oliver$$b5
000600080 7001_ $$aDubin, Grzegorz$$b6
000600080 7001_ $$0P:(DE-HGF)0$$aMenezes, Filipe$$b7$$eCorresponding author
000600080 7001_ $$0P:(DE-H253)PIP1100543$$aCzarna, Anna$$b8$$eCorresponding author
000600080 773__ $$0PERI:(DE-600)1491411-6$$a10.1021/acs.jmedchem.2c01887$$gVol. 66, no. 6, p. 4009 - 4024$$n6$$p4009 - 4024$$tJournal of medicinal chemistry$$v66$$x0095-9065$$y2023
000600080 8564_ $$uhttps://bib-pubdb1.desy.de/record/600080/files/grygier-et-al-2023-silmitasertib-%28cx-4945%29-a-clinically-used-ck2-kinase-inhibitor-with-additional-effects-on-gsk3%CE%B2-and.pdf$$yOpenAccess
000600080 8564_ $$uhttps://bib-pubdb1.desy.de/record/600080/files/grygier-et-al-2023-silmitasertib-%28cx-4945%29-a-clinically-used-ck2-kinase-inhibitor-with-additional-effects-on-gsk3%CE%B2-and.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000600080 909CO $$ooai:bib-pubdb1.desy.de:600080$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000600080 9101_ $$0I:(DE-HGF)0$$6P:(DE-H253)PIP1086294$$aExternal Institute$$b4$$kExtern
000600080 9101_ $$0I:(DE-HGF)0$$6P:(DE-H253)PIP1100543$$aExternal Institute$$b8$$kExtern
000600080 9131_ $$0G:(DE-HGF)POF4-6G3$$1G:(DE-HGF)POF4-6G0$$2G:(DE-HGF)POF4-600$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bForschungsbereich Materie$$lGroßgeräte: Materie$$vPETRA III (DESY)$$x0
000600080 9141_ $$y2023
000600080 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000600080 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000600080 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000600080 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000600080 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000600080 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000600080 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000600080 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000600080 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000600080 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ MED CHEM : 2022$$d2023-10-21
000600080 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000600080 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000600080 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ MED CHEM : 2022$$d2023-10-21
000600080 9201_ $$0I:(DE-H253)HAS-User-20120731$$kDOOR ; HAS-User$$lDOOR-User$$x0
000600080 980__ $$ajournal
000600080 980__ $$aVDB
000600080 980__ $$aUNRESTRICTED
000600080 980__ $$aI:(DE-H253)HAS-User-20120731
000600080 9801_ $$aFullTexts